ArticleMethods in molecular biology (Clifton, N.J.)2025
In Vivo Fermentation Production of RNA Interference Agents.
Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Novel in vivo approaches for manufacturing RNA agents are warranted to complement conventional methods such as in vitro transcription and chemical synthesis. Recently, we have identified and utilized unique tRNA-fused pre-miRNA carriers to establish a robust RNA molecular bioengineering technology that allows one to consistently and efficiently produce target, bioengineered or biologic RNA molecules bearing small interfering RNA (siRNA) payloads (BioRNA/siRNA). Here, we describe a streamlined method with a detailed protocol for the rational design, molecular cloning, heterologous overexpression, and chromatography purification of large quantity (multi-milligrams from 0.25 L of bacterial culture) and high quality (> 98% homogeneity and <5 endotoxin unit/μg RNA) of target BioRNA/siRNA molecules that are ready for basic research as well as experimental therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.